Blood compatibility of a newly developed trileaflet mechanical heart valve.

An ideal heart valve prosthesis, which has both the flow dynamic properties and blood compatibility of a tissue valve prosthesis and the durability of a mechanical prosthesis, does not exist. The Triflo trileaflet mechanical heart valve (MHV; Triflo Medical Inc., Irvine, CA) is a newly developed MHV prosthesis with the following design goals: central flow, minimal flow disturbance and stasis around the hinge region, and durability. The current study was conducted to evaluate the blood compatibility of a 29 mm Triflo MHV in the mitral position of eight calves for 5 months without any postoperative anticoagulation. Whole blood platelet aggregometry and the Xylum Clot Signature Analyzer (Xylum Corporation, Scarsdale, NY) were used to evaluate the postoperative changes in platelet and coagulation functions. Full autopsies, histological examinations of major internal organs, and scanning electron microscopy analyses of the explants were performed. Early termination occurred in two cases; one was because of valve thrombosis on the 25th day, and the other was killed because of a nonvalvular complication on the 105th day. The valve thrombosis was attributed to prolonged ventricular fibrillation at the time of valve replacement surgery. Whole blood platelet aggregometry and clot signature analyzer parameters did not show any sign of activation of platelets or the coagulation system. No hemolysis was observed. There was no macroscopic valve thrombosis or embolism observed in the remaining seven cases. Scanning electron microscopy analyses showed clean leaflet and valve ring surfaces, with only occasional minute platelet aggregations. Excellent blood compatibility of the Triflo MHV was demonstrated in this study.

[1]  F. R. Rosendaal,et al.  Thromboembolic and Bleeding Complications in Patients With Mechanical Heart Valve Prostheses , 1994, Circulation.

[2]  G. Laub,et al.  Early and late-phase events after valve replacement with the St. Jude Medical prosthesis in 1200 patients. , 1994, The Journal of thoracic and cardiovascular surgery.

[3]  N. Smedira,et al.  Real-Time Three-Dimensional Echocardiographic Study of Left Ventricular Function After Infarct Exclusion Surgery for Ischemic Cardiomyopathy , 2000, Circulation.

[4]  A. Yoganathan,et al.  Prosthesis-induced hemolysis: mechanisms and quantification of shear stress. , 1998, The Journal of heart valve disease.

[5]  H Harasaki,et al.  Particle image velocimetry investigation of intravalvular flow fields of a bileaflet mechanical heart valve in a pulsatile flow. , 2000, The Journal of heart valve disease.

[6]  L. Edmunds,et al.  Thrombotic and bleeding complications of prosthetic heart valves. , 1987, The Annals of thoracic surgery.

[7]  H Reul,et al.  Cavitation of mechanical heart valves under physiologic conditions. , 1992, The Journal of heart valve disease.

[8]  N. Fiotti,et al.  D-dimer and anticoagulation in patients with mechanical prosthetic heart valves. A 2-year follow-up. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[9]  H Reul,et al.  In vivo evaluation of a trileaflet mechanical heart valve. , 1994, ASAIO journal.

[10]  S. E. Jorgensen,et al.  The role of pressure damage in pathogenesis of the downer cow syndrome. , 1982, American journal of veterinary research.

[11]  A. Fontaine,et al.  Identification of Peak Stresses in Cardiac Prostheses: A Comparison of Two‐Dimensional Versus Three‐Dimensional Principal Stress Analyses , 1996, ASAIO journal.

[12]  G. van Melle,et al.  St. Jude Medical valve prosthesis: an analysis of long-term outcome and prognostic factors. , 1997, The Journal of thoracic and cardiovascular surgery.

[13]  K. Bailey,et al.  Variability in anticoagulation control predicts thromboembolism after mechanical cardiac valve replacement: a 23-year population-based study. , 1997, Mayo Clinic proceedings.

[14]  H. Harasaki,et al.  Evaluation of platelet and coagulation function in different animal species using the xylum clot signature analyzer. , 2001 .

[15]  T. Hoffmann,et al.  The Xylum Clot Signature Analyzer: a dynamic flow system that simulates vascular injury. , 1998, Thrombosis research.

[16]  H. Harasaki,et al.  Whole blood platelet aggregation in humans and animals: a comparative study. , 1999, The Journal of surgical research.

[17]  A bovine model for detecting high intensity transient signals originating from mechanical heart valves. , 1999 .

[18]  F Clerc,et al.  Long-term results of valve replacement with the St. Jude Medical prosthesis. , 1995, The Journal of thoracic and cardiovascular surgery.

[19]  H. Harasaki,et al.  A comprehensive hematologic study in calves with total artificial hearts. , 1995, ASAIO journal.

[20]  M. Gharib,et al.  Vortex shedding as a mechanism for free emboli formation in mechanical heart valves. , 2000, Journal of biomechanical engineering.

[21]  N. Maugeri,et al.  Circulating platelet/polymorphonuclear leukocyte mixed–cell aggregates in patients with mechanical heart valve replacement , 2000, American journal of hematology.

[22]  J. Skoularigis,et al.  Frequency and severity of intravascular hemolysis after left-sided cardiac valve replacement with Medtronic Hall and St. Jude Medical prostheses, and influence of prosthetic type, position, size and number. , 1993, The American journal of cardiology.

[23]  A. Moritz,et al.  Blood rheology after cardiac valve replacement with mechanical prostheses or bioprostheses. , 1991, The American journal of cardiology.

[24]  H. Harasaki,et al.  Platelets are deposited early post-operatively on the leaflet of a mechanical heart valve in sheep without post-operative anticoagulants or antiplatelet agents. A scanning electron microscopic observation of the pyrolytic carbon surface in a mechanical heart valve. , 1996, ASAIO journal.